Veracyte/VCYT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Veracyte

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

Ticker

VCYT

Sector

Healthcare

Trading on

NASDAQ

Industry

Healthcare Facilities

CEO

Marc Stapley

Employees

815

Headquarters

South san francisco, United States

Veracyte Metrics

BasicAdvanced
$1.6B
Market cap
-
P/E ratio
-$0.93
EPS
1.70
Beta
-
Dividend rate
$1.6B
1.69922
$30.52
$18.61
706K
5.003
4.687
0.009
0.009
-5.78%
-6.20%
-6.08%
4.225
1.418
6.385
60.256
20.66%
-122.16%
45.39%

What the Analysts think about Veracyte

Analyst Ratings

Majority rating from 9 analysts.
Buy

Veracyte Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1.85% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$97M
-1.33%
Net income
-$1.8M
-93.62%
Profit margin
-1.85%
-93.56%

Veracyte Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 87.41%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.12
-$0.41
-$0.39
-$0.02
-
Expected
-$0.15
-$0.15
-$0.09
-$0.16
-$0.03
Surprise
-21.44%
179.62%
317.86%
-87.41%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Veracyte stock?

Veracyte (VCYT) has a market cap of $1.6B as of June 17, 2024.

What is the P/E ratio for Veracyte stock?

The price to earnings (P/E) ratio for Veracyte (VCYT) stock is 0 as of June 17, 2024.

Does Veracyte stock pay dividends?

No, Veracyte (VCYT) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Veracyte dividend payment date?

Veracyte (VCYT) stock does not pay dividends to its shareholders.

What is the beta indicator for Veracyte?

Veracyte (VCYT) has a beta rating of 1.7. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Veracyte stock price target?

The target price for Veracyte (VCYT) stock is $29.83, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Veracyte stock

Buy or sell Veracyte stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing